Literature DB >> 8305286

Stereoselective cyclooxygenase inhibition in cellular models by the enantiomers of ketoprofen.

N Suesa1, M F Fernandez, M Gutierrez, M J Rufat, E Rotllan, L Calvo, D Mauleon, G Carganico.   

Abstract

The pharmacological activity of rac-ketoprofen and its enantiomers was investigated in vitro using different cellular models. The effect of these compounds on arachidonic acid metabolism was assessed by measuring the inhibition of prostanoid generation under the action of several agonists. Thus, we have evaluated the inhibition of (1) thromboxane B2 synthesis in rabbit platelets and human polymorphonuclear leukocytes (PMNs), (2) prostaglandin E2 synthesis in three cultured cells, namely human umbilical vein endothelial cells (HUVEC), human keratinocytes, and mouse macrophage-like P388D1 cells. The IC50 values found for (+)-(S)-ketoprofen were in the range between 0.1 nM and 0.8 microM, being slightly lower in all models than those found for rac-ketoprofen (0.4 nM-3 microM). On the other hand (-)-(R)-ketoprofen showed inhibition of cyclooxygenase only at concentrations two or three orders of magnitude higher than those required for the (+)-(S) enantiomer. These results, obtained with cell types of relevance for inflammatory processes and with compounds of high optical purity, demonstrate that the prostanoid biosynthesis inhibition caused by the drug rac-ketoprofen is exclusively due to its dextrorotatory enantiomer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8305286     DOI: 10.1002/chir.530050805

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  12 in total

Review 1.  Chirality and nonsteroidal anti-inflammatory drugs.

Authors:  P J Hayball
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 2.  Preclinical and clinical development of dexketoprofen.

Authors:  D Mauleón; R Artigas; M L García; G Carganico
Journal:  Drugs       Date:  1996       Impact factor: 9.546

3.  Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination.

Authors:  N G Grubb; D W Rudy; D C Brater; S D Hall
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

4.  Mechanisms involved in the attenuation of intestinal toxicity induced by (S)-(+)-ketoprofen in re-fed rats.

Authors:  Ana I Nieto; Francesc Cabré; Francisco J Moreno; Catalina Alarcón de la Lastra
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

5.  Gastric toxicity of racemic ketoprofen and its enantiomers in rat: oxygen radical generation and COX-expression.

Authors:  C Alarcón de la Lastra; A Nieto; M J Martín; F Cabré; J M Herrerías; V Motilva
Journal:  Inflamm Res       Date:  2002-02       Impact factor: 4.575

6.  Comparison of dexketoprofen trometamol and dipyrone in the treatment of renal colic.

Authors:  Juan Sánchez-Carpena; Javier Sesma-Sánchez; Carlos Sánchez-Juan; Santiago Tomás-Vecina; Dolors García-Alonso; Jordi Rico-Salvadó; Mónica Forns; Maria Mas; Isabel Paredes; Remei Artigas
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

7.  A multicentre, randomised, double-blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain.

Authors:  H Zippel; A Wagenitz
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

8.  Modulation by stereoselective inhibition of cyclo-oxygenase of electromechanical coupling in the guinea-pig isolated renal pelvis.

Authors:  P Santicioli; G Carganico; S Meini; S Giuliani; A Giachetti; C A Maggi
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

9.  Pharmacokinetics and bioavailability of ketoprofen when compounded with iron dextran for use in nursing piglets.

Authors:  Kristen J Reynolds; Ron Johnson; Robert M Friendship; Jennifer Brown; Saad Enouri; Ronette Gehring; Terri L O'Sullivan
Journal:  Can Vet J       Date:  2021-11       Impact factor: 1.008

10.  Novel Activities of Select NSAID R-Enantiomers against Rac1 and Cdc42 GTPases.

Authors:  Tudor I Oprea; Larry A Sklar; Jacob O Agola; Yuna Guo; Melina Silberberg; Joshua Roxby; Anna Vestling; Elsa Romero; Zurab Surviladze; Cristina Murray-Krezan; Anna Waller; Oleg Ursu; Laurie G Hudson; Angela Wandinger-Ness
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.